Document is current

Any future updates will be listed below

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

Crossref DOI link: https://doi.org/10.1186/1471-2407-14-965

Published: 2014-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

About CrossMark